Home Drug IndexClinical Monograph

Oral Rehydration Solution (ORS) Uses, Benefits, Dosage & Side Effects | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Electrolyte and Fluid Replacement

Subclass

Oral Rehydration Salts (WHO reduced osmolarity formula)

Speciality

Gastroenterology,

Schedule (India)

Not Scheduled (OTC)

Routes

Oral

Formulations

Powder for oral solution: Sachets to prepare 1 litre of solution (WHO low-osmolarity formula – 245 mOsm/L)
Ready-to-drink solution: 200 mL, 500 mL, 1 litre bottles

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Acute Diarrhoea – Prevention and Treatment of Dehydration

Assessment-based Rehydration Protocol:

Dehydration Status	Clinical Features	Rehydration Dose	Maintenance After Each Stool
No dehydration (Plan A)	Well, alert; eyes normal; drinks normally; skin pinch retracts immediately	Not required	<2 yrs: 50–100 mL; 2–10 yrs: 100–200 mL; >10 yrs/adults: 200–500 mL
Some dehydration (Plan B)	Restless/irritable; sunken eyes; drinks eagerly; skin pinch retracts slowly (<2 sec)	75 mL/kg over 4 hours	Reassess after 4 hours; continue maintenance
Severe dehydration (Plan C)	Lethargic/unconscious; very sunken eyes; drinks poorly; skin pinch retracts very slowly (>2 sec)	Start IV fluids first; switch to ORS once able to drink	Continue as per clinical response

Clinical Notes:

Reassess hydration status every 4 hours during rehydration phase
ORS should be given by cup and spoon; avoid bottle feeding in infants
Continue breastfeeding in infants throughout rehydration
Freshly prepared ORS solution should be used within 24 hours

2. Cholera – Rehydration in Moderate Dehydration

Parameter	Recommendation
Starting dose	75–100 mL/kg over 4–6 hours
Titration	Not applicable
Usual maintenance dose	200–500 mL after each watery stool
Maximum dose	As tolerated; guided by clinical hydration status

Clinical Notes:

In severe cholera with shock, initiate IV Ringer's Lactate first
ORS serves as sole rehydration therapy in mild-to-moderate cases
Zinc supplementation (as per ICMR/IAP) should accompany ORS in children

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Duration	Label Status	Evidence Basis
Mild dehydration due to heat exposure/exertional sweating	500–1000 mL as tolerated	Short-term during exposure	OFF-LABEL	Indian public health protocols; occupational medicine practice
Post-exercise rehydration	500 mL–1 L after exertion	Single episode	OFF-LABEL	Sports medicine practice; limited formal evidence

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

Acute Diarrhoea – Prevention and Treatment of Dehydration

Age Group	Weight	No Dehydration (Plan A) — Per Stool	Some Dehydration (Plan B) — Over 4 Hours
<6 months	<5 kg	50 mL	200–400 mL
6 months–<2 years	5–10 kg	50–100 mL	400–700 mL
2–5 years	10–19 kg	100–200 mL	700–900 mL
5–10 years	19–30 kg	200 mL	900–1400 mL
>10 years	>30 kg	200–400 mL	1500–2200 mL

Minimum Age: No lower age limit; suitable from birth including neonates

Safety Monitoring:

Administer with cup and spoon; avoid bottle feeding
Monitor for signs of overhydration (periorbital oedema, respiratory distress)
Assess hydration status every 1–2 hours during active rehydration
If vomiting occurs, wait 10 minutes and resume at slower rate
Continue breastfeeding during ORS therapy

Severe Dehydration Protocol:

Initiate IV fluids (Ringer's Lactate) immediately
Transition to ORS once patient can tolerate oral intake
Specialist/facility-based management required

Secondary Indications — Paediatrics (Off-label, if any)

Indication	Dose	Duration	Label Status	Evidence Basis
Mild exercise-induced dehydration	Same as acute diarrhoea protocols; 50–200 mL based on age	As needed	OFF-LABEL; Specialist guidance	Indian paediatric sports medicine practice
Vomiting-associated dehydration (without diarrhoea)	Small frequent sips; 5 mL every 1–2 minutes	Until vomiting resolves	OFF-LABEL	IAP clinical practice

Age Restriction: No minimum age restriction; neonates may receive ORS under careful supervision to prevent aspiration.

Renal Adjustments

Normal renal function: No adjustment required
Chronic kidney disease (CKD): Use with caution; avoid large volumes without monitoring electrolytes
Oliguria/Anuria: Avoid oral rehydration; specialist input mandatory
Haemodialysis/Peritoneal dialysis: Volume intake must align with fluid restriction protocols; electrolyte monitoring essential

Hepatic adjustment

Contraindications

Complete mechanical bowel obstruction
Paralytic ileus
Intractable vomiting precluding oral intake
Severe dehydration with haemodynamic instability (requires IV fluids first)
Altered consciousness with risk of aspiration
Known hypersensitivity to any component of the formulation

Cautions'

Hypernatraemic dehydration — rehydrate gradually over 12–24 hours to avoid cerebral oedema
Glucose-galactose malabsorption — standard ORS may worsen diarrhoea
Diabetes mellitus — glucose content may transiently affect glycaemic control; monitor blood glucose
Heart failure — fluid overload risk; use controlled volumes with close monitoring
Renal impairment — risk of electrolyte imbalance; monitor serum sodium and potassium
Elderly patients — higher risk of aspiration and fluid overload

Pregnancy

Parameter	Recommendation
Safety status	Safe for use in pregnancy
Preferred alternative	ORS is the preferred first-line therapy for diarrhoeal dehydration in pregnancy
When to use	Recommended for mild-to-moderate dehydration; IV fluids for severe dehydration
Monitoring	Monitor for fluid overload in pre-eclampsia or gestational hypertension

Lactation

Parameter	Recommendation
Compatibility	Fully compatible with breastfeeding
Drug levels in milk	Not applicable (oral electrolyte solution, not systemically absorbed)
Preferred alternative	None; ORS is first-line
Infant monitoring	Continue breastfeeding alongside ORS; monitor infant's hydration and feeding adequacy

Elderly

Starting dose: Begin with moderate volumes (100–200 mL at a time); assess tolerance
Titration: Increase volume based on hydration response and tolerance
Extra risks:
- Fluid overload in those with cardiac or renal comorbidities
- Aspiration risk if swallowing dysfunction or altered sensorium present
- Hyponatraemia or hypernatraemia if improper dilution
Monitoring: Assess bowel sounds, respiratory status, fluid balance, and serum electrolytes

Major drug interactionsMajor drug interactions

None documented.

ORS is not systemically absorbed and does not undergo hepatic metabolism. No clinically significant pharmacokinetic or pharmacodynamic interactions are known.

Moderate drug interactions

Interacting Drug	Interaction	Recommendation
Drugs with narrow therapeutic index (digoxin, lithium, phenytoin)	Diarrhoea-related altered gut transit may affect absorption	Monitor drug levels; adjust timing if feasible
Metformin	Diarrhoea may reduce absorption	Space doses 1–2 hours apart from ORS if possible
Oral antibiotics	Rapid gut transit may reduce bioavailability	Consider timing or parenteral alternatives in severe diarrhoea

Common Adverse effects

Abdominal bloating
Mild nausea
Flatulence
Transient increase in stool frequency initially
Unpleasant taste (in some formulations)

Serious Adverse effects

Rare; generally related to misuse or administration errors:

Hypernatraemia — if solution prepared with insufficient water or excessive salt
Fluid overload — in patients with cardiac or renal impairment; manifests as oedema, pulmonary congestion
Aspiration pneumonia — in unconscious patients or infants given ORS via bottle
Severe electrolyte disturbance — in renal failure without monitoring

Monitoring requirements'

Timing	Parameters
Baseline	Assess dehydration severity clinically; weight; vital signs
During therapy (every 2–4 hours)	Hydration status (skin turgor, mucous membranes, urine output); weight; presence of vomiting
In high-risk patients	Serum sodium, potassium, glucose; fluid balance charting
After rehydration	Confirm resolution of dehydration signs; transition to maintenance and dietary recovery

Brands in India

Electral® (FDC)
ORS WHO Formula (Cipla, Wallace, multiple generic manufacturers)
ORSL® (flavoured variants)
Walyte® (Wallace)
Pedialyte® (Abbott) — paediatric formulation
Enerzal ORS®
Multiple government-supplied generic ORS sachets

Price range (INR)

Formulation	Approximate Price	Notes
Powder sachets (for 1 L)	₹5–15 per sachet	NLEM-regulated; widely available in government facilities
Ready-to-drink (200 mL)	₹15–30 per bottle	Private retail
Ready-to-drink (500 mL–1 L)	₹35–60 per bottle	Private retail

NLEM Status: ORS is included in NLEM 2022; price-controlled formulation.

Clinical pearls

Use only WHO-recommended reduced osmolarity ORS (245 mOsm/L); older high-osmolarity formulations are obsolete
Freshly prepare ORS daily; discard unused solution after 24 hours
Homemade sugar-salt solution (6 level teaspoons sugar + ½ level teaspoon salt in 1 litre water) may be used only if commercial ORS is unavailable — mixing accuracy is critical
In infants: continue breastfeeding alongside ORS; it improves outcomes and reduces dehydration severity
Zinc supplementation (10–20 mg/day for 10–14 days) is recommended alongside ORS in children <5 years with acute diarrhoea
Severe dehydration or shock requires IV fluids (Ringer's Lactate) first — ORS is introduced once oral intake is tolerable

Version

RxIndia v1.0 — 28 May 2025

Reference

- NLEM 2022
- Indian Pharmacopoeia / National Formulary of India
- IAP Guidelines for Management of Acute Diarrhoea
- ICMR Guidelines on Diarrhoeal Disease Management
- WHO/UNICEF Joint Statement on Clinical Management of Acute Diarrhoea
- AIIMS Hospital Protocols
- API Textbook of Medicine

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...